Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the Clinical Priorities Advisory Group next plans to consider funding for Abiraterone in a prioritsation round.

NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting evidence to support the routine commissioning of abiraterone in this indication and it was ranked as the top priority for routine commissioning. This position is being kept under review, although currently there is no requirement for another meeting of the Clinical Priorities Advisory Group to reprioritise this policy, and the policy will be progressed as soon as recurrent funding is identified.